Trump Halt To US Funding For WHO: Making Global Health, Government Organization Potent Issues
Executive Summary
Selling government efficiency as a campaign issue has not been an easy task for Democrats. COVID-19 – and especially support for international responses – may present a new opportunity.
You may also be interested in...
Trump Administration Signals Deference To Congress On Drug Pricing Policy
In a marked departure from previous years, budget proposal offers few specifics on cost reductions, but the $135bn savings estimate is a tacit endorsement of the Grassley-Wyden bill in the Senate.
NIH Director Collins Stays On: Continuity For ‘Moonshot’ – And Barrier To ‘March In’
For industry, the sole health agency head held over from the Obama Administration means the ‘Moonshot’ priorities will move forward – and one possible threat to pricing is cut off.
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.